The KDM3B Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma epithelial cell line. This product enables loss-of-function studies of KDM3B, a histone demethylase with critical roles in chromatin regulation and gene expression. The polyclonal format provides a heterogeneous pool of edited cells, permitting functional analysis in a cancer-relevant epithelial model without clonal selection.
The A-549 host cell line was originally established from a lung adenocarcinoma of a 58-year-old male. These cells represent a widely used model of alveolar Type II epithelial cells, exhibiting key features of pulmonary barrier function and xenobiotic metabolism. Their robust growth characteristics and genetic tractability make them well-suited for CRISPR-based gene disruption studies targeting epigenetic regulators.
KDM3B encodes a histone H3 lysine 9 (H3K9) demethylase that removes mono- and dimethyl marks, thereby promoting transcriptional activation. This enzyme functions as a coactivator for transcription factors including androgen receptor and TCF/LEF, and acts downstream of HIF1A and retinoic acid receptors. KDM3B directly regulates downstream targets such as CCND1, MYC, and SLC2A1, integrating signals from Wnt/beta-catenin, hypoxia, and retinoic acid pathways. It interacts with beta-catenin, androgen receptor, and chromatin remodeling complexes to orchestrate gene expression programs linked to proliferation and metabolism.
In the A-549 adenocarcinoma context, KDM3B disruption is expected to alter H3K9 methylation landscapes at promoters of cell cycle and metabolic genes, potentially impairing proliferation and modulating hypoxia responses. Given the emerging role of KDM3B in tumor suppression and metabolic regulation, this knockout model provides a relevant platform to dissect epigenetic mechanisms underlying lung cancer progression and drug sensitivity.
This polyclonal knockout cell population supports a range of experimental approaches, including western blotting for histone methylation marks (H3K9me1/2), RT-qPCR for target gene expression (CCND1, SLC2A1), ChIP-qPCR to assess locus-specific H3K9 methylation, and cell proliferation assays (MTT, BrdU). Additional applications include RNA-seq for transcriptome profiling, flow cytometry for cell cycle analysis, migration/invasion assays, hypoxia exposure experiments, and colony formation assays. Researchers can employ these cells to investigate chromatin modifier function, cancer epigenetics, and drug resistance mechanisms. For further technical information, please contact Ascent Research.
